Recently, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort EP") obtained the regulatory approval by National Medical Administration Products (NMPA) in China for its independently developed FireMagic™ TrueForce™ Ablation Catheter.
FireMagic™ TrueForce™ Ablation Catheter is used in conjunction with Columbus™ 3D EP Navigation System and OptimAblate™ Cardiac Generator for the treatment of refractory, recurrent, symptomatic and paroxysmal Atrial Fibrillation.
While working with Columbus™ 3D EP Navigation, FireMagic™ TrueForce™ Ablation Catheter can accurately indicate the catheter force value and vector while contacting the tissue, construct the ablation index, provide the indication of ablation energy and the dynamics of ablation lesion formation in real time to achieve the precise treatment.
The approval of the FireMagic™ TrueForce™ Ablation Catheter further enriches catheters product line of MicroPort EP and enhances the company's core competitiveness and market expansion ability. In the future, MicroPort EP will continue to invest in technology research and development and product innovation and offer comprehensive solutions for diagnosis and therapy of EP interventions for doctors and patients worldwide.